Salbutamol/budesonide
Medication
From Wikipedia, the free encyclopedia
Albuterol/budesonide, sold under the brand name AIRSUPRA, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma.[1][2] It is a combination of albuterol, a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid.[1][2] It is inhaled using a pressurized metered-dose inhaler.[1][2]
| Combination of | |
|---|---|
| Albuterol | short-acting β2-agonist |
| Budesonide | inhaled corticosteroid |
| Clinical data | |
| Trade names | Airsupra |
| Other names | PT027, albuterol/budesonide |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The most common side effects include headache, oral candidiasis, cough, and difficulty speaking.[2]
AIRSUPRA was approved for medical use in the United States in January 2023.[2][3] It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved by the US Food and Drug Administration (FDA).[2] It is the first product containing an inhaled corticosteroid to be approved by the FDA as a reliever treatment (rather than as a controller) for asthma.[2]
Medical uses
History
The efficacy of salbutamol/budesonide to reduce the risk of severe asthma attacks was evaluated in participants with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study.[2]
